Safety and Immunogenicity Study of EgyVax Vaccine Candidate for Prophylaxis of COVID-19 Infection

PHASE1UnknownINTERVENTIONAL
Enrollment

45

Participants

Timeline

Start Date

February 6, 2022

Primary Completion Date

October 31, 2022

Study Completion Date

June 30, 2023

Conditions
COVID-19
Interventions
DRUG

EgyVax Vaccine Candidate

EgyVax Inactivated SARS-CoV-2 vaccine candidate, equivalent to 70 mcg inactivated SARS-CoV-2 total protein. Alum adjuvant 2% 50 µl (equivalent to 0.5 mg AlOH). Equivalent volume of Saline 0.9% to each vaccine dose. Each vial contains 0.5 ml representing one dose 70 mcg of inactivated SARS-CoV-2 virus with alum adjuvant or two doses of 35 mcg of inactivated SARS-CoV-2 virus with alum adjuvant

DRUG

Placebo

0.5ml Saline (0.9%)

Trial Locations (1)

Unknown

RECRUITING

Cairo University Hospitals (Al-Manial Specialized University Hospital), Cairo

Sponsors

Lead Sponsor

All Listed Sponsors
collaborator

Veterinary Serum & Vaccine Research Institute (VSVRI), Egypt

UNKNOWN

collaborator

The Supreme Council of University Hospitals, Egypt

UNKNOWN

collaborator

Ministry of Higher Education and Scientific Research, Egypt

UNKNOWN

lead

Eva Pharma

INDUSTRY